FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:241-250 January 19, 2006 Number 3 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Ratjen, F. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Abnormal homeostasis of the volume of airway surface liquid in patients with cystic fibrosis is thought to produce defects in mucus clearance and airway defense. Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function.

Methods A total of 24 patients with cystic fibrosis were randomly assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily with or without pretreatment with amiloride. Mucus clearance and lung function were measured during 14-day baseline and treatment periods.

Results Long-term inhalation of hypertonic saline without pretreatment with amiloride (i.e., with placebo pretreatment) resulted in a sustained (8 hours) increase in 1-hour rates of mucus clearance, as compared with those with amiloride pretreatment (14.0±2.0 vs. 7.0±1.5 percent, respectively; P=0.02) and increased 24-hour rates of mucus clearance over baseline. Furthermore, inhalation of hypertonic saline with placebo improved the forced expiratory volume in one second (FEV₁) between the baseline period and the treatment period (mean difference, 6.62 percent; 95 percent confidence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV₁ (mean difference, 2.9 percent; 95 percent confidence interval, –2.2 to 8.0; P=0.23). Forced vital capacity (FVC), the forced expiratory flow between 25 and 75 percent of FVC (FEF_25–75), and respiratory symptoms also significantly improved in patients treated with hypertonic saline and placebo, whereas the residual volume as a proportion of total lung capacity (RV:TLC) did not change in either group. A comparison of the changes in lung function in the two groups showed no significant difference. In vitro data suggested that sustained hydration of airway surfaces was responsible for the sustained improvement in mucus clearance, whereas inhibition of osmotically driven water transport by amiloride accounted for the observed loss of clinical benefit.

Conclusions In patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of mucus clearance and improved lung function. This treatment may protect the lung from insults that reduce mucus clearance and produce lung disease.

Source Information

From the University of North Carolina at Chapel Hill Cystic Fibrosis Research and Treatment Center (S.H.D., W.D.B., M.R.K., R.T., R.C.B.) and the Center for Environmental Medicine, Asthma and Lung Biology (W.D.B., K.L.Z.) — both in Chapel Hill.

Drs. Donaldson and Bennett contributed equally to this article.

Address reprint requests to Dr. Donaldson at 6019 Thurston Bowles Bldg., CB# 7248, University of North Carolina at Chapel Hill Research and Treatment Center, Chapel Hill, NC 27599, or at scott_donaldson{at}med.unc.edu.

Full Text of this Article

Related Letters:

Hypertonic Saline for Cystic Fibrosis
Aziz I., Kastelik J. A., Zarogiannis S., Hatzoglou C., Gourgoulianis K., Kuver R., Lee S. P., Bye P. T.P., Elkins M. R., Donaldson S. H., Tarran R., Boucher R. C., Ratjen F.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1848-1851, Apr 27, 2006. Correspondence

This article has been cited by other articles:

• Bergsson, G., Reeves, E. P., McNally, P., Chotirmall, S. H., Greene, C. M., Greally, P., Murphy, P., O'Neill, S. J., McElvaney, N. G. (2009). LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline. J. Immunol. 183: 543-551 [Abstract] [Full Text]  
• Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., Montgomery, A. B. (2009). Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection. Chest 135: 1610-1618 [Abstract] [Full Text]  
• Coote, K., Atherton-Watson, H. C., Sugar, R., Young, A., MacKenzie-Beevor, A., Gosling, M., Bhalay, G., Bloomfield, G., Dunstan, A., Bridges, R. J., Sabater, J. R., Abraham, W. M., Tully, D., Pacoma, R., Schumacher, A., Harris, J., Danahay, H. (2009). Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating Protease. J. Pharmacol. Exp. Ther. 329: 764-774 [Abstract] [Full Text]  
• Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., Cooper, P. J. (2009). Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis. Chest 135: 1223-1232 [Abstract] [Full Text]  
• Bradford, E. M., Sartor, M. A., Gawenis, L. R., Clarke, L. L., Shull, G. E. (2009). Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G886-G898 [Abstract] [Full Text]  
• Abbott, J (2009). Health-related quality of life measurement in cystic fibrosis: advances and limitations. Chronic Respiratory Disease 6: 31-41 [Abstract]  
• Voynow, J. A., Rubin, B. K. (2009). Mucins, Mucus, and Sputum. Chest 135: 505-512 [Abstract] [Full Text]  
• LiPuma, J. J., Rathinavelu, S., Foster, B. K., Keoleian, J. C., Makidon, P. E., Kalikin, L. M., Baker, J. R. Jr. (2009). In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species. Antimicrob. Agents Chemother. 53: 249-255 [Abstract] [Full Text]  
• Ratjen, F., Bush, A. (2008). Amiloride: Still a Viable Treatment Option in Cystic Fibrosis?. Am. J. Respir. Crit. Care Med. 178: 1191-1192 [Full Text]  
• MacDonald, K. D., McKenzie, K. R., Henderson, M. J., Hawkins, C. E., Vij, N., Zeitlin, P. L. (2008). Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L933-L940 [Abstract] [Full Text]  
• Rowe, S. M., Jackson, P. L., Liu, G., Hardison, M., Livraghi, A., Solomon, G. M., McQuaid, D. B., Noerager, B. D., Gaggar, A., Clancy, J. P., O'Neal, W., Sorscher, E. J., Abraham, E., Blalock, J. E. (2008). Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease. Am. J. Respir. Crit. Care Med. 178: 822-831 [Abstract] [Full Text]  
• Nakagami, Y., Favoreto, S. Jr, Zhen, G., Park, S.-W., Nguyenvu, L. T., Kuperman, D. A., Dolganov, G. M., Huang, X., Boushey, H. A., Avila, P. C., Erle, D. J. (2008). The Epithelial Anion Transporter Pendrin Is Induced by Allergy and Rhinovirus Infection, Regulates Airway Surface Liquid, and Increases Airway Reactivity and Inflammation in an Asthma Model. J. Immunol. 181: 2203-2210 [Abstract] [Full Text]  
• Rogers, C. S., Abraham, W. M., Brogden, K. A., Engelhardt, J. F., Fisher, J. T., McCray, P. B. Jr., McLennan, G., Meyerholz, D. K., Namati, E., Ostedgaard, L. S., Prather, R. S., Sabater, J. R., Stoltz, D. A., Zabner, J., Welsh, M. J. (2008). The porcine lung as a potential model for cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L240-L263 [Abstract] [Full Text]  
• Jaques, A., Daviskas, E., Turton, J. A., McKay, K., Cooper, P., Stirling, R. G., Robertson, C. F., Bye, P. T. P., LeSouef, P. N., Shadbolt, B., Anderson, S. D., Charlton, B. (2008). Inhaled Mannitol Improves Lung Function in Cystic Fibrosis. Chest 133: 1388-1396 [Abstract] [Full Text]  
• Hirsh, A. J., Zhang, J., Zamurs, A., Fleegle, J., Thelin, W. R., Caldwell, R. A., Sabater, J. R., Abraham, W. M., Donowitz, M., Cha, B., Johnson, K. B., St. George, J. A., Johnson, M. R., Boucher, R. C. (2008). Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease. J. Pharmacol. Exp. Ther. 325: 77-88 [Abstract] [Full Text]  
• Elizur, A., Cannon, C. L., Ferkol, T. W. (2008). Airway Inflammation in Cystic Fibrosis*. Chest 133: 489-495 [Abstract] [Full Text]  
• Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J. Jr., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., Rosenblatt, R., Vender, R. L., Hazle, L., Sabadosa, K., Marshall, B. (2007). Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. Am. J. Respir. Crit. Care Med. 176: 957-969 [Abstract] [Full Text]  
• Donaldson, S. H., Boucher, R. C. (2007). Sodium Channels and Cystic Fibrosis. Chest 132: 1631-1636 [Abstract] [Full Text]  
• Boyle, M. P. (2007). Adult Cystic Fibrosis. JAMA 298: 1787-1793 [Abstract] [Full Text]  
• Itani, O. A., Lamb, F. S., Melvin, J. E., Welsh, M. J. (2007). Basolateral chloride current in human airway epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L991-L999 [Abstract] [Full Text]  
• Manz, F. (2007). Hydration and Disease. J. Am. Coll. Nutr. 26: 535S-541S [Abstract] [Full Text]  
• Ramsey, B. W. (2007). Use of Lung Imaging Studies as Outcome Measures for Development of New Therapies in Cystic Fibrosis. Proc Am Thorac Soc 4: 359-363 [Abstract] [Full Text]  
• Ramsey, B. W. (2007). Outcome Measures for Development of New Therapies in Cystic Fibrosis: Are We Making Progress and What Are the Next Steps?. Proc Am Thorac Soc 4: 367-369 [Full Text]  
• Mayer-Hamblett, N., Ramsey, B. W., Kronmal, R. A. (2007). Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis. Proc Am Thorac Soc 4: 370-377 [Abstract] [Full Text]  
• Goss, C. H., Quittner, A. L. (2007). Patient-reported Outcomes in Cystic Fibrosis. Proc Am Thorac Soc 4: 378-386 [Abstract] [Full Text]  
• Donaldson, S. H., Corcoran, T. E., Laube, B. L., Bennett, W. D. (2007). Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research. Proc Am Thorac Soc 4: 399-405 [Abstract] [Full Text]  
• Quinton, P. M. (2007). Cystic Fibrosis: Lessons from the Sweat Gland. Physiology 22: 212-225 [Abstract] [Full Text]  
• Accurso, F. J. (2007). Update in Cystic Fibrosis 2006. Am. J. Respir. Crit. Care Med. 175: 754-757 [Full Text]  
• Goss, C. H, Burns, J. L (2007). Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis. Thorax 62: 360-367 [Abstract] [Full Text]  
• Enderby, B., Doull, I. (2007). Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?. Arch. Dis. Child. 92: 195-196 [Full Text]  
• Taylor, L. M, Kuhn, R. J (2007). Hypertonic Saline Treatment of Cystic Fibrosis. The Annals of Pharmacotherapy 41: 481-484 [Abstract] [Full Text]  
• Warwick, W. J., Braverman, J. (2007). Letter to the Editor. Chronic Respiratory Disease 4: 51-51  
• Harris, M., Firsov, D., Vuagniaux, G., Stutts, M. J., Rossier, B. C. (2007). A Novel Neutrophil Elastase Inhibitor Prevents Elastase Activation and Surface Cleavage of the Epithelial Sodium Channel Expressed in Xenopus laevis Oocytes. J. Biol. Chem. 282: 58-64 [Abstract] [Full Text]  
• Kuver, R., Wong, T., Klinkspoor, J. H., Lee, S. P. (2006). Absence of CFTR is associated with pleiotropic effects on mucins in mouse gallbladder epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G1148-G1154 [Abstract] [Full Text]  
• Tino, G. (2006). Clinical Year in Review IV: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Infections, and Mycobacterial Disease. Proc Am Thorac Soc 3: 650-653 [Full Text]  
• Rubin, B. K., Kater, A. P., Goldstein, A. L. (2006). Thymosin {beta}4 Sequesters Actin in Cystic Fibrosis Sputum and Decreases Sputum Cohesivity in Vitro.. Chest 130: 1433-1440 [Abstract] [Full Text]  
• Levin, M. H., Sullivan, S., Nielson, D., Yang, B., Finkbeiner, W. E., Verkman, A. S. (2006). Hypertonic Saline Therapy in Cystic Fibrosis: EVIDENCE AGAINST THE PROPOSED MECHANISM INVOLVING AQUAPORINS. J. Biol. Chem. 281: 25803-25812 [Abstract] [Full Text]  
• Okada, S. F., Nicholas, R. A., Kreda, S. M., Lazarowski, E. R., Boucher, R. C. (2006). Physiological Regulation of ATP Release at the Apical Surface of Human Airway Epithelia. J. Biol. Chem. 281: 22992-23002 [Abstract] [Full Text]  
• Randell, S. H., Boucher, R. C., for the University of North Carolina Virtual Lung, (2006). Effective Mucus Clearance Is Essential for Respiratory Health. Am. J. Respir. Cell Mol. Bio. 35: 20-28 [Full Text]  
• Aziz, I., Kastelik, J. A., Zarogiannis, S., Hatzoglou, C., Gourgoulianis, K., Kuver, R., Lee, S. P., Bye, P. T.P., Elkins, M. R., Donaldson, S. H., Tarran, R., Boucher, R. C., Ratjen, F. (2006). Hypertonic saline for cystic fibrosis.. NEJM 354: 1848-1851 [Full Text]  
• Gondker, A (2006). Inhaled hypertonic saline, mechanisms, and improved lung function in cystic fibrosis. Thorax 61: 283-283 [Full Text]  
• Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., Bye, P. T.P., the National Hypertonic Saline in Cystic Fibrosis, (2006). A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis. NEJM 354: 229-240 [Abstract] [Full Text]  
• Ratjen, F. (2006). Restoring Airway Surface Liquid in Cystic Fibrosis. NEJM 354: 291-293 [Full Text]